41st week of 2014 patent applcation highlights part 36 |
Patent application number | Title | Published |
20140302057 | INHIBITORS OF METASTASIS - The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis. | 2014-10-09 |
20140302058 | HUMAN ANTI IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES - The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors. | 2014-10-09 |
20140302059 | COMPOSITIONS AND METHODS FOR CANCER AND CANCER STEM CELL DETECTION AND ELIMINATION - In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded RNA-specific adenosine deaminases, or ADAR, enzymes. In alternative embodiments, the invention provides compositions and methods for treating, ameliorating or preventing diseases and conditions responsive to the inhibition of cell differentiation and/or self-renewal of dysfunctional cells, cancer cells, leukemia cells, hematopoietic stem cells or cancer stem cells, e.g., leukemia or Chronic Myeloid Leukemia (CML). In alternative embodiments, the invention provides compositions and methods for inhibiting a Sonic Hedgehog (Shh) pathway, e.g., by using a Smoothened (SMO) protein inhibitor. In alternative embodiments, the invention provides compositions and methods for measuring or determining, or predicting, chronic myelogenous leukemia (CML) progression, Leukemic Stem Cell (LSC) generation and/or tyrosine kinase inhibitor resistance. In alternative embodiments, the invention provides compositions and methods for determining or measuring the effectiveness of a treatment, a drug, a therapy or a diet for eliminating, killing or reducing the amounts of a leukemic stem cell (LSC) or cells. | 2014-10-09 |
20140302060 | Gene Signature for the Prediction of NF-kappaB Activity - Methods for predicting NF-kappaB (NF-kB) activity in a tumor, and more particularly to methods for predicting survival and therapeutic outcome, and selecting therapy in subjects with tumors, e.g., adenocarcinomas, e.g., lung adenocarcinomas and melanomas. | 2014-10-09 |
20140302061 | BIOMARKERS FOR TSLP TREATMENT - The present invention relates to biomarker responsive to treatment with a TSLP antagonist. | 2014-10-09 |
20140302062 | HERPES SIMPLEX VIRUS - The present invention relates, in general to herpes simplex virus (HSV) and, particular, to antibodies that are specific for glycoprotein D (gD) of HSV. The invention also relates to prophylactic and therapeutic uses of such antibodies. | 2014-10-09 |
20140302063 | INFLUENZA VIRUS ANTIBODY COMPOSITIONS - The present invention relates to unique CDR3 amino acid sequences, and to antibodies comprising said sequences. Also provided are therapeutic applications of said antibodies for use in treating or preventing influenza infection, diagnostic applications of said antibodies for use in detecting influenza virus, potency testing of influenza virus vaccines, and screening applications of said antibodies for use in designing a universal influenza vaccine. | 2014-10-09 |
20140302064 | OPTIMIZED ANTI-CD3 VARIABLE REGIONS - The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 2014-10-09 |
20140302065 | SOLUBLE UROKINASE RECEPTOR (SUPAR) IN DIABETIC KIDNEY DISEASE - Methods and compositions are provided for diagnosing and treating a diabetic kidney disease (DKD) in an individual. In aspects of the methods, the levels of soluble circulating urokinase receptor (suPAR) in the blood are measured to predict a DKD, diagnose a DKD, or provide a prognosis pertaining to a DKD. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided. | 2014-10-09 |
20140302066 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES - This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates. | 2014-10-09 |
20140302067 | PERSIMMON LEAF-DERIVED POLYSACCHARIDE FRACTION HAVING IMMUNE FUNCTION-ENHANCING ACTIVITY AND METHOD PRODUCING THE SAME - A persimmon leaf-derived polysaccharide fraction, a preparation method thereof, and use thereof, the persimmon leaf-derived polysaccharide fraction including, based on the total weight of the polysaccharide fraction, 70-90 wt % of neutral sugar and 10-30 wt % of uronic acid. | 2014-10-09 |
20140302068 | MicroRNA Biomarkers for Diagnosing Parkinson's Disease - The identification, development and validation of plasma-based circulating microRNA (miRNAs) biomarkers useful in determining if a subject has Parkinson's disease (PD), is at increased risk of developing PD, or has PD that is progressing or is in remission are presented. | 2014-10-09 |
20140302069 | MODULATORS OF C3A RECEPTORS - Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated cardiovascular diseases are described. The use of the compounds in stimulating or suppressing an immune response is also described together with pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts. | 2014-10-09 |
20140302070 | NOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSES - In one embodiment, the present invention provides a new isoform of human PD1 (Δ42PD1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines In one embodiment, Δ42PD1 can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8 | 2014-10-09 |
20140302071 | PEPTIDES FOR VACCINE - The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy. | 2014-10-09 |
20140302072 | NON-NATURAL MIC PROTEINS - This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with a heterologous α3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the α3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified α3 domain of a MIC protein. | 2014-10-09 |
20140302073 | IMMUNOGENIC PROTEIN PAS N 1 FROM BAHIA GRASS POLLEN - The present invention relates generally to novel recombinant polypeptides of Bahia grass pollen and to genetic sequences encoding same. More particularly, the present invention is directed to Pas n 1 polypeptides and derivatives, and fragments thereof and genetic sequences encoding same. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications including, but not limited to, applications in the context of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to the Bahia grass pollen. | 2014-10-09 |
20140302074 | Pat-LM1 Epitopes and Methods for Using Same - The present disclosure relates generally to epitopes of an antibody known as PAT-LM1, and methods for using said epitopes. | 2014-10-09 |
20140302075 | ASPARTYL-TRNA SYNTHETASES - The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability. | 2014-10-09 |
20140302076 | IMMUNOGENIC COMPOSITIONS AND METHODS THEREFOR - The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunise an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the N-terminus and further at the C-terminus and/or at one or more exposed loops of the capsomere. | 2014-10-09 |
20140302077 | LIVE ATTENUATED INFLUENZA VIRUS - Provided are live attenuated influenza A and B viruses as well as a composition, influenza A and B genes, a vector with a respective gene, a host cell comprising such vector, a method for preparing a live attenuated influenza A or B virus and a use of the influenza viruses as a vaccine. An influenza A virus contains a NP-gene, which includes a silent mutation at one or more positions selected from nucleotide 1467, nucleotide 1473, nucleotide 1500, nucleotide 1503, nucleotide 1512, nucleotide 1515, nucleotide 1518, nucleotide 1521, and nucleotide 1524 of SEQ ID No: 1. A PA gene includes a silent mutation at one or more positions corresponding to a position selected from nucleotides 2100 and 2103 of SEQ ID No: 3. | 2014-10-09 |
20140302078 | HAEMOPHILUS INFLUENZAE TYPE B - Polypeptides comprising various amino acid sequences derived from | 2014-10-09 |
20140302079 | NOVEL INFLUENZA HEMAGGLUTININ PROTEIN-BASED VACCINES - Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins. | 2014-10-09 |
20140302080 | STABILIZED HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE (ENV) TRIMER VACCINES AND METHODS OF USING SAME - The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention. | 2014-10-09 |
20140302081 | HIV-1 GP120 MINI V3 LOOP AND USES THEREOF - The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies. | 2014-10-09 |
20140302082 | NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 1B, HEPATITIS C VIRUS GENOME-REPLICATING CELLS TRANSFECTED WITH THE SAME, AND METHOD FOR PRODUCING INFECTIOUS HEPATITIS C VIRUS PARTICLES - A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided. | 2014-10-09 |
20140302083 | PORPHYROMONAS GINGIVALIS POLYPEPTIDES AND NUCLEOTIDES - The present invention relates to isolated | 2014-10-09 |
20140302084 | IMMUNOGENIC PROTEIN CONJUGATES AND METHOD FOR MAKING AND USING THE SAME - Production of protein conjugate vaccines by use of transpeptidase enzymes, such as sortase enzymes. For example, homogenous immunoconjugates (e.g., a population of molecules having the same structure) formed by conjugating an antigenic polypeptide and a bacterial capsule component are provided. In certain aspects, methods for generating an immune response to | 2014-10-09 |
20140302085 | USE OF GK-1 PEPTIDE EXPRESSED ON M13 FILAMENTOUS PHAGE AS PHARMACEUTICAL INGREDIENT TO ENHANCE THE EFFICIENCY OF THE IMMUNE RESPONSE INDUCED BY VACCINE OR PATHOGEN ANTIGENS - The present invention is directed to the use of FGK-1 immunopotentiator, composed by the peptide named GK-1, characterized by the sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A and linked to the pVIII surface protein of M13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchoalveolar lavages. | 2014-10-09 |
20140302086 | Pharmaceutical Composition Comprising Cannabinoids Having Reduced Psychoactivity through the Combination of CBD and Non-decarboxylated THC - The present invention relates to a pharmaceutical composition comprising non-decarboxylated Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof. | 2014-10-09 |
20140302087 | MANUFACTURE OF VACCINES THAT CONTAIN BOTH HEPATITIS B VIRUS SURFACE ANTIGEN AND SURFACTANT - When preparing HBsAg for use in a combination vaccine, it is known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification. | 2014-10-09 |
20140302088 | COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES - Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells. | 2014-10-09 |
20140302089 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND/OR TREATING AN HIV DISEASE IN HUMANS - The present invention relates to pharmaceutical compositions comprising a mixture of a specific HIV antigen and a non-pathogenic living bacterium. Said specific HIV antigen comprises one or more epitopes from Gag and/or Pol proteins and is preferably under a particulate form. Said bacterium is preferably | 2014-10-09 |
20140302090 | NOVEL VACCINE - The invention relates to the use of an influenza antigen preparation obtainable by the following process, in the manufacture of an intradermal flu vaccine:
| 2014-10-09 |
20140302091 | METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES - Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus. | 2014-10-09 |
20140302092 | MUTANT REPLICON DERIVED FROM GENOME OF HEPATITIS C VIRUS J6CF STRAIN - A nucleic acid includes the 5′ untranslated region, a virus protein-coding region including the NS3 protein coding sequence, the NS4A protein coding sequence, the NS4B protein coding sequence, the NS5A protein coding sequence, and the NS5B protein coding sequence, and the 3′ untranslated region of the HCV J6CF genome in that order from the 5′ to 3′ direction. The NS4A protein coding sequence has a mutation for substituting alanine at position 1680 with glutamic acid, as determined on the basis of the amino acid sequence of the precursor protein of the J6CF strain. | 2014-10-09 |
20140302093 | MICROORGANISMS CARRYING A TUMOR ANTIGEN - The present invention pertains to microorganisms of the species | 2014-10-09 |
20140302094 | VACCINE - There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by | 2014-10-09 |
20140302095 | MYCOBACTERIUM TUBERCULOSIS PORINS AND TOXINS AND RELATED METHODS - Provided herein are isolated polypeptides comprising the amino-terminal domain of | 2014-10-09 |
20140302096 | COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS - The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention. | 2014-10-09 |
20140302097 | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS - Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendritic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate. | 2014-10-09 |
20140302098 | YEAST-BASED VACCINES AS IMMUNOTHERAPY - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 2014-10-09 |
20140302099 | Ophthalmic Composition Containing Cyclosporine And method For Preparing Same - The present invention relates to an ophthalmic composition containing cyclosporine as an active ingredient and comprising propylene glycol, a surfactant, and purified water, and to a method for preparing same. The ophthalmic composition according to the present invention is in the form of a clear and transparent solution, and increases patient compliance due to the absence of side effects, such as cloudy vision or a scorching sensation, and has a high bioavailability due to improved cyclosporine absorbance in the ocular tissue, which is the target organ. | 2014-10-09 |
20140302100 | METHODS AND BIOMARKERS FOR ANALYSIS OF COLORECTAL CANCER - The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients. | 2014-10-09 |
20140302101 | NATURAL HAIRSTYLE HOLDING PRODUCT CONTAINING LEVAN AS A FILM-FORMER - A hairstyle holding composition formed of natural or naturally derived ingredients, the composition comprising a hairstyle holding resin, wherein the hairstyle holding resin consists essentially of a low viscosity levan, wherein the levan produces a low intrinsic viscosity dispersion in water having particle sizes in the range of from about 50 to about 200 nm, and wherein the composition further includes at least one natural or naturally derived additive, wherein the at least one additive is selected from the group consisting of natural oils, natural antimicrobial substances, a natural fragrance, a natural emulsifier, a natural viscosity controller and a natural liquefied or gaseous form hydrocarbon to serve as a propellant. | 2014-10-09 |
20140302102 | COSMETIC COMPOSITION FOR THE LIPS CONTAINING SPHERICAL MICROPARTICLES - The present invention discloses a cosmetic for the lips comprising spherical micro particles of silica, emollients and gel, as well as cosmetically acceptable excipients. | 2014-10-09 |
20140302103 | HAIR CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION - A hair care composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equal to 1500 and mixtures thereof and mixtures thereof or, by weight of said hair care composition; wherein an emulsifier is selected from the group consisting of anionic, non-ionic, cationic, amphoteric and mixtures thereof wherein the average particle size of the pre-emulsified oil in water emulsion is from about 20 nanometers to 20 microns; and a cationic surfactant system wherein the composition is stable with respect to one of the following measures selected from emulsion particle size, viscosity or visual phase separation and mixtures thereof. | 2014-10-09 |
20140302104 | CONJUGATED POLYMERIC MATERIAL AND USES THEREOF - Disclosed are compositions comprising collagen covalently bound to particles, wherein covalent bonds are formed between reactive groups of the collagen and reactive groups of the particles, and wherein the particles have an average particle diameter ranging from 20 to 1000 nanometers. Also disclosed are various methods that utilize the compositions. | 2014-10-09 |
20140302105 | COSMETIC COMPOSITION COMPRISING SILICA AEROGEL PARTICLES, A GEMINI SURFACTANT AND A SOLID FATTY SUBSTANCE - The subject of the present invention is a cosmetic composition of oil-in-water type comprising: (1) hydrophobic silica aerogel particles having a specific surface area per unit of mass (S | 2014-10-09 |
20140302106 | POWDERY HAIR COSMETICS - Powdery compositions comprising core-shell particles are provided. The shell contains particles of at least one hydrophobized metal oxide powder and the liquid core contains, based on the weight of the core, about 20.0% by weight to 100.0% by weight, in particular about 50.0% by weight to 100.00% by weight, of at least one polyol of formula (I), wherein n represents an integer from 1 to 4. The powdery compositions are suitable for temporarily shaping keratin-containing fibers. For example, the use of said compositions on human hair resulted in an elastic hairstyle having volume. Hair so treated was given natural gloss. | 2014-10-09 |
20140302107 | OXIDIZING BLEACH COMPOSITION - The invention provides an aqueous bleaching solution for substrate treatment. The aqueous bleaching solution features a source of oxidant and a plurality of optically functional nanoparticles. The optically functional nanoparticles are nanoparticles in the range of about 0.1 nanometers to about 400 nanometers in size. The aqueous bleaching solution may optionally include one or more an oxidant-stable surfactants and optionally, one or more oxidant-stable polymers, and adjuncts. The optically functional nanoparticles are extremely stable in the aqueous bleaching solution and remain substantially suspended in the aqueous bleaching solution due to their extremely small size despite having an average density greater than that of the bleaching solution. The optically functional nanoparticles provide at least one optical functional benefit to the bleaching solution owing to their uniform and stable suspension throughout the solution, including such benefits as uniform light absorption, light and radiation scattering, fluorescent emission, phosphorescent emission, coloration, and visual aesthetic benefits and the like. Further, optically functional benefits include those benefits provided to a substrate or surface treated with the aqueous bleaching solutions whereby the optically functional property is transferred either temporarily or permanently to the substrate or surface following contact with bleaching solutions containing the optically functional nanoparticles. | 2014-10-09 |
20140302108 | Nail Discoloration and Fungus Treatment - A system and method for treating human nails afflicted with fungus is now disclosed. The system comprises a hydrogel dressing or pad, a topical agent consisting of a nanosilver treatment agent, a topical carrier in which said treatment agent is dispersed, and an adhesive for securing the hydrogel and treatment agent to a nail in need of such treatment. A kit, method and regimen for treatment of the nail are also disclosed. | 2014-10-09 |
20140302109 | Nanotubes and Compositions Thereof - The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes. | 2014-10-09 |
20140302110 | Magnetic field-controlled movable bio-scaffold and constructing method thereof - Disclosed are a magnetic field-controlled movable bio-scaffold and a method for constructing the same. The bio-scaffold is highly biocompatible and can readily move to a target site under the control of an external magnetic field. | 2014-10-09 |
20140302111 | COMPOSITIONS AND METHODS FOR DENTAL TISSUE REGENERATION - Provided is a method for regenerating dental tissue, which can include contacting a scaffold containing Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF, with a dental tissue so as to promote odontoblastic differentiation of a progenitor cell, promote progenitor cell migration into the dental tissue, or regenerate the dental tissue. Also provided is a composition for regeneration of dental tissue, which can include a scaffold and Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF. | 2014-10-09 |
20140302112 | BONE MATRIX COMPOSITIONS AND METHODS - Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract. | 2014-10-09 |
20140302113 | SYSTEMS, DEVICES, AND METHODS FOR EMBEDDING DRUG MOLECULES INTO MEDICAL CATHETERS OR TUBES - The present disclosure relates to methods for embedded drug molecules into medical catheters, tubes, and other medical devices. The catheter, tube, or other medical device is capable of releasing drugs for extended periods of time. Drugs can be loaded into the wall thereof through diffusion from a loading solution. A counterintuitive approach of using undissolved drug particulates in the loading solution is employed in some embodiments. The drug in the wall of the device and in the loading solution can be in dynamic equilibrium, yielding stable and easy-to-manufacture products. Heat can be used to significantly speed up the drug loading. | 2014-10-09 |
20140302114 | IMPLANTABLE MEDICAL DEVICES WITH INCREASED IMMUNE TOLERANCE, AND METHODS FOR MAKING AND IMPLANTING - The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs). | 2014-10-09 |
20140302115 | DRUG DELIVERY SYSTEM BASED ON POLYETHYLENE VINYLACETATE COPOLYMERS - A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby,
| 2014-10-09 |
20140302116 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY - The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof. In some embodiments, a structure includes a substrate; and a multilayer film coated on the substrate, wherein adjacent layers of the multilayer film are associated with one another via one or more non-covalent interactions, wherein the multilayer film comprises a first nucleic acid agent present at a loading density, and further wherein the multilayer film is characterized in that, when the structure is placed on a subject so that the multilayer film contacts cells, the first nucleic acid agent is released with a profile characterized by a feature selected from the group consisting of 1) being a burst-free release; 2) being a sustained release; and 3) exhibiting in vitro and/or in vivo biological effectiveness. | 2014-10-09 |
20140302117 | TISSUE PRODUCTS INCLUDING A TEMPERATURE CHANGE COMPOSITION CONTAINING PHASE CHANGE COMPONENTS WITHIN A NON-INTERFERING MOLECULAR SCAFFOLD - Wiping products, such as facial tissues, contain a temperature change composition that can provide a cooling sensation when contacted with the skin of a user. The temperature change composition includes a phase change material and a non-interfering molecular scaffold. The phase change materials, in one embodiment, can have a relatively high heat of fusion. When undergoing a phase change, the temperature change composition absorbs heat and thereby provides a cooling feeling or cooling sensation to the skin of a user. | 2014-10-09 |
20140302118 | HYDROUS ADHESIVE SKIN PATCH - The purpose of the present invention is to provide a hydrous adhesive skin patch which contains lidocaine and can be applied in a uniform thickness easily. This hydrous adhesive skin patch comprises a support and an adhesive agent layer arranged on the support, wherein lidocaine or a pharmacologically acceptable salt thereof, a hydrophilic adhesive agent, and diethylene glycol or a diethylene glycol monoalkyl ether are contained in the adhesive agent layer. The diethylene glycol monoalkyl ether is preferably at least one compound selected from the group consisting of diethylene glycol monomethyl ether, diethylene glycol monoethyl ether and diethylene glycol monobutyl ether. | 2014-10-09 |
20140302119 | MICROVESICLES CARRYING SMALL INTERFERING RNAS PREPARATION METHODS AND USES THEREOF - Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles containing interfering RNAs can stably, high efficiently and specifically deliver interfering RNAs, microvesicles containing interfering RNAs can be used to treat related diseases. | 2014-10-09 |
20140302120 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR - The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma. | 2014-10-09 |
20140302121 | Cannabinoid Receptor Binding Agents, Compositions and Methods - A composition comprising a cannabinoid receptor binding agent contained in a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin. | 2014-10-09 |
20140302122 | FUNGAL-SPECIFIC METALLOPROTEASES AND USES THEREOF - The present invention relates to methods of reducing, delaying, preventing and/or inhibiting the progression of a | 2014-10-09 |
20140302123 | PRODUCTS USEFUL FOR THE TREATMENT OF MALIGNANT NEOPLASMS OF THE HUMAN NERVOUS SYSTEM - The application provides products, which may trigger pro-apoptotic or pro-death effects on neoplastic cells and/or tissues of the human nervous system, more particularly on neoplastic cells and/or tissues of the human CNS. The products of the application can be used as anti-proliferative or tumoricid agents in the treatment and/or palliation and/or prevention of neoplasms of the human nervous system, more particularly of glioblastoma or brain stem glioma. Therefore, the application also relates to compositions, such as pharmaceutical compositions or drugs, which comprise at least one of said products, as well as to the biotechnological and medical applications of said products and compositions. | 2014-10-09 |
20140302124 | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION - Influenza virus infection and the resulting complications are a significant global public health problem and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Improving humoral immunity to influenza is the target of current conventional influenza vaccines, however, these are generally not cross-protective. On the contrary, cell-mediated immunity generated by primary influenza infection provides substantial protection against serologically distinct viruses due to recognition of cross-reactive T cell epitopes, often from internal viral proteins conserved between viral subtypes. Efforts are underway to develop a universal flu vaccine that would stimulate both the humoral and cellular immune responses leading to long-lived memory. Such a universal vaccine should target conserved influenza virus antibody and T cell epitopes that do not vary from strain to strain. The present invention incorporates immunoproteomics to uncover novel MHC class I specific epitopes derived from influenza-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against various different influenza strains. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in influenza infection, and serves as a universal vaccine candidate complementary to current vaccines. | 2014-10-09 |
20140302125 | Methods for treating cardiovascular disorders - There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient. | 2014-10-09 |
20140302126 | Rhein or diacerein compositions - The invention relates to pharmaceutical compositions comprising rhein or diacerein or salts or esters or prodrugs thereof, optionally with one or more pharmaceutically acceptable excipients. The invention also relates to the methods for preparing such compositions. | 2014-10-09 |
20140302127 | Novel formulation of metaxalone - The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments. | 2014-10-09 |
20140302128 | Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease - This invention relates to a biological oil composition, preferably obtained from a copepod, most preferably the copepod | 2014-10-09 |
20140302129 | HUMAN LUBRICATION GEL - Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site. | 2014-10-09 |
20140302130 | SILICA-MATRIX FORMING COMPOSITIONS, MATERIALS FORMED THEREFROM, AND METHODS OF USING THE SAME - The present invention provides compositions for encapsulation of biomaterials in a silica-matrix. The present invention also provides methods of making silica-matrix encapsulated biomaterials, and to methods of using silica-matrix encapsulated biomaterials. In one embodiment, the present invention provides a method of encapsulating mammalian cells in a silica-matrix while maintaining metabolic activity. In another embodiment, the present invention provides a method of purifying cancer cells using a silica-matrix. | 2014-10-09 |
20140302131 | ORAL FORMULATIONS CONTAINING HYALURONIC ACID FOR SUSTAINED DRUG RELEASE - The present invention discloses a tablet or a capsule for oral administration comprising 0.5-0% (w/w) hyaluronic acid or a salt thereof, an active pharmaceutical ingredient (API), and a coating. | 2014-10-09 |
20140302132 | PHARMACEUTICAL COMPOSITION COMPRISING NANOCRYSTALS - The present invention relates to processes for the manufacture of suspensions comprising one or more water soluble or water insoluble pharmaceutical or nutraceutical active ingredients with a particle size in the range of from 0.01 to 10 micron. More specifically, suspensions prepared by this process can be used to formulate pharmaceutical compositions, especially in liquid fill capsules. | 2014-10-09 |
20140302133 | CAPSULE WITH INTERNAL DIAPHRAGM - A capsule of, for instance, hard gelatin for holding a substance such as medicine, food supplements or similar materials includes a capsule body having a closed and an opposed open end with a predetermined length defined between the ends. A diaphragm having a closed end and an opposed open end and a predetermined length there between seals off the body and provides a first compartment to hold a first medicine, food supplement, etc. A cap is applied to the body as is conventional in capsules. The space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second medicine, food supplement, etc. The contents of each compartment may be wet or dry (e.g., powder or liquid.) This two-compartment capsule has particular relationships between the length along an axis of the capsule of the diaphragm to that of the body, and particular dimensional parameters relating to the sidewall contact seal between the outer portion of the diaphragm and the inner wall of the body, to provide adequate capsule sealing and stability during and after manufacture. | 2014-10-09 |
20140302134 | FORMULATION FOR THE CONTROLLED RELEASE OF ONE OR SEVERAL SUBSTANCES IN THE DIGESTIVE TRACT OF A MAMMAL - The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value. | 2014-10-09 |
20140302135 | Microencapsulation as a strategy for implementation and environmental safe-guarding of a paratransgenic approach to control of vector-borne diseases - A microparticle comprising a pesticidal agent encapsulated within a polymer coating, the polymer coating comprising an oil-soluble dye wherein the oil-soluble dye and the polymer coating increases the pesticidal agent's ability to withstand UV radiation, a method of manufacturing the microparticle and a method of using the microparticle to control pests | 2014-10-09 |
20140302136 | DELIVERY SYSTEM FOR SAW PALMETTO EXTRACT AND CAROTENOID - A medicine delivery system delivers medicine such as a dietary supplement to improve prostate health and includes an outer capsule containing a saw palmetto extract and an inner capsule within the outer capsule and containing a carotenoid. The outer capsule is formed to dissolve in the stomach when ingested to release the saw palmetto extract into the stomach and the inner capsule is formed to pass into the duodenum to dissolve and release the carotenoid into the duodenum. | 2014-10-09 |
20140302137 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES - The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. | 2014-10-09 |
20140302138 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING CARBAMAZEPINE - An extended release matrix tablet for once daily administration comprising Carbamazepine or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients and process for preparing the same and is bioequivalent to FDA approved Carbamazepine extended release tablet formulations (TEGRETOL®-XR). | 2014-10-09 |
20140302139 | Controlled Release and Taste Masking Oral Pharmaceutical Compositions - The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach. | 2014-10-09 |
20140302140 | GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS - Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective. | 2014-10-09 |
20140302141 | Triple Combination Release Multi-layered Tablet - This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet ( | 2014-10-09 |
20140302142 | COMPOSITIONS AND METHDS FOR ENHANCING PENETRATION OF BIOLOGICALLY ACTIVE SUBSTANCES INTO TISSUES OR ORGANS - According to this invention, compositions and methods for increasing the extent of penetration of a biologically active substance into the tissues and organs are proposed, the methods comprising administration of the biologically active substance in combination with one or more chaotropic agents, e.g., ammonium sulfate. | 2014-10-09 |
20140302143 | Controlled Release and Taste Masking Oral Pharmaceutical Compositions - The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating. | 2014-10-09 |
20140302144 | MULTI-LAYERED INJECTABLE SELF-ASSEMBLING PEPTIDE SCAFFOLD HYDROGELS FOR LONG-TERM SUSTAINED RELEASE OF HUMAN ANTIBODIES - The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts. The formulation can provide sustained release of antibody and antibody fragments, in particular, IgG. Antibody diffusivities can be decreased with increasing hydrogel nanofiber density, providing a means to control the release kinetics. | 2014-10-09 |
20140302145 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USING CARBONATE APATITE NANOPARTICLES - A principal object of the present invention is to provide a pharmaceutical composition that can produce a high antitumor effect by efficiently delivering a drug with antitumor activity to tumor tissues with the aid of carbonate apatite nanoparticles. The present invention provides a pharmaceutical composition including carbonate apatite nanoparticles with an average particle size of at most 50 nm containing a drug with antitumor activity and a pharmacologically acceptable solvent in which the carbonate apatite nanoparticles containing the drug are dispersed. | 2014-10-09 |
20140302146 | Ophthalmic Aqueous Composition - The present invention provides an ophthalmic aqueous composition having an oil-in-water emulsion including a vegetable oil, a non-ionic surfactant, and a terpenoid, wherein an average particle diameter of emulsion particles is within the range of 30 nm to 300 nm. | 2014-10-09 |
20140302147 | RESPIRABLE AGGLOMERATES OF POROUS CARRIER PARTICLES AND MICRONIZED DRUG - Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby. | 2014-10-09 |
20140302148 | CANNABINOID FORMULATIONS - The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications. | 2014-10-09 |
20140302149 | Selective Chemokine Modulation - A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-γ inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum. | 2014-10-09 |
20140302150 | DPP-IV INHIBITOR FORMULATIONS - The present invention relates to a pharmaceutical formulation, characterized by comprising a DPP-IV inhibitor and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. | 2014-10-09 |
20140302151 | METHODS AND COMPOSITIONS FOR TREATING PAIN - Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy. | 2014-10-09 |
20140302152 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE - The invention relates to a solid pharmaceutical composition, the composition comprising eslicarbazepine acetate and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of granules, and wherein at least 90% of the granules of the composition have a particle size of 90 μm or more, and/or wherein at least 50% of the granules of the composition have a particle size of 250 μm or more. The invention also relates to a process for producing a granular composition. Further, the invention relates to the use of the composition in therapy and, in particular, in the treatment or prevention a disorder selected from epilepsy, neuropathic pain, migraine, fibromyalgia an affective disorders. | 2014-10-09 |
20140302153 | METHODS AND TREATMENT FOR ALLERGIES AND INFLAMMATION ASSOCIATED WITH GASTROINTESTINAL DISEASES - Methods of the prophylaxis of the development of allergy in a patient at risk of sensitization to an antigen(s) or allergen(s) due to impaired gastrointestinal functions include administering a mast cell inhibitor, e.g., ketotifen, e.g., ketotifen fumarate. Methods for prophylactically treating, reducing, delaying or controlling gastrointestinal disorders include administering a mast cell stabilizer, e.g., ketotifen to a patient in need thereof. Pharmaceutical preparation, composition for use in methods described, are also disclosed. Also disclosed are methods of prophylaxis or treating gastrointestinal and esophageal inflammation, and methods for the prophylaxis of the development of additional allergies to a newly introduced substance in a patient with a preexisting allergy. Such methods include delivery of a mast cell stabilizer, e.g., ketotifen. Oral and topical administration are contemplated within the scope of the methods. | 2014-10-09 |
20140302154 | MAGNETIC TRANSDUCERS - Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer. | 2014-10-09 |
20140302155 | PRODUCTION OF A HUMAN BETA CELL LINE FROM AN EARLY POST NATAL PANCREAS - The present invention relates to a method for preparing commercial scale quantities of human functional beta cells and to the establishment of cell lines from non-foetal pancreatic tissues. It also relates to a method of diagnosis using beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing to generate human Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation. They have a gene expression profile that resembles to adult beta cells. In addition, the human beta cell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities. | 2014-10-09 |
20140302156 | RIGID SHAPED ARTICLE FOR THE TREATMENT OF ITCHING - The invention concerns a rigid shaped article essentially consisting of a plurality of mutually adhering grains of sand provided with a coating consisting of wax, for the elimination or relief of itching. In a particular embodiment of the invention, the wax essentially consists of beeswax. | 2014-10-09 |